Activity

ferentiate between periodized fluctuations in load.Weakley, J, Chalkley, D, Johnston, R, García-Ramos, A, Townshend, A, Dorrell, H, Pearson, M, Morrison, M, and Cole, M. Criterion validity, and interunit and between-day reliability of the FLEX for measuring barbell velocity during commonly used resistance training exercises. J Strength Cond Res 34(6) 1519-1524, 2020-The aim of this study was to assess the criterion validity, interunit reliability (accounting for technological and biological variance), and between-day reliability of a novel optic laser device (FLEX) for quantifying mean concentric velocity. To assess the validity against a three-dimensional motion capture system and interunit reliability with both technological and biological variation, 18 men and women completed repetitions at 20, 40, 60, 80, 90, and 100% of one repetition maximum in the free-weight barbell back squat and bench press. To assess interunit (technological only) reliability, a purpose-built, calibrated rig completed a set protocol with 2 devices. To assess between-day reliabilityning loads.Introduction The purpose of this investigation is to assess the current utilization of telehealth capabilities at academic orthopaedic departments in the United States and to determine how practice patterns have been directly influenced by the coronavirus disease 19 (COVID-19) pandemic. Methods Orthopaedic surgery programs participating in the Electronic Residency Application Service were identified. One hundred seventy-five (175) programs were presented with a seven-item questionnaire addressing whether each program is using telehealth services in response to the COVID-19 pandemic. Results Of the 175 Electronic Residency Application Service participant orthopaedic programs, 168 responded for a total response rate of 96%. Of the 106 institutions using telehealth services, 88 (83%) cited the COVID-19 pandemic as the impetus for implementation of telehealth services. Institutions located in the Northeast and South regions were markedly more likely to offer telehealth services. Heat map analysis demonstrates an associative overlap of regional “hot spots” with direct comparison of COVID-19 cases in the United States and orthopaedic departments providing telehealth services. garsorasib molecular weight Discussion This study demonstrates the impressive measures academic orthopaedic institutions are taking to meet the needs of our patients by identifying a notable increase in new telehealth offerings throughout the United States with a positive correlation with COVID-19 disease burden.Objective Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-acting intranasal therapy for depression and is currently under development for suicidality. The authors sought to determine the efficacy of adjunctive intranasal esketamine in major depressive disorder (MDD). Data sources A systematic search of PubMed/MEDLINE was conducted up to January 2019, in addition to abstracts of major psychiatric meetings held since 2010. Searches were conducted by cross-referencing the term intranasal with the term esketamine. Where necessary, authors and/or study sponsors were contacted in order to obtain a copy of the presentation as well as any pertinent study details. Study selection 241 study abstracts were initially identified and reviewed. Selected studies were randomized, double-blind clinical trials comparing adjunctive intranasal esketamine to adjunctive placebo for MDD. Data extraction Data were extracted independently by two of the authors. A random effects model was used to calculate the standardized mean difference (SMD) between esketamine and placebo (intranasal saline) in the Montgomery-Asberg Depression Rating Scale (MADRS) score change from baseline to endpoint, serving as the primary outcome of the study. Results Five trials with 774 patients were pooled. Adjunctive esketamine was significantly more effective than placebo for MADRS score change, response, and remission (N = 774, SMD = 0.36, 95% CI = 0.24-0.49, P less then .0001; response risk ratio [RR] = 1.40, 95% CI = 1.22-1.61, P less then .0001; remission RR = 1.45, 95% CI = 1.20-1.75, P less then .0001). Results remained statistically significant regardless of differences in the study sample, fixed vs new/optimized baseline antidepressants. Conclusions Adjunctive intranasal esketamine for patients with MDD who are either treatment-resistant or acutely suicidal appears to be an effective treatment strategy.Objective To evaluate efficacy, effect on mood, and safety of deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD) at different target sites. Data sources Electronic records from databases MEDLINE, EMBASE, and CENTRAL up to November 2019 were searched. Search terms included OCD, depression, and DBS. Study selection Eight randomized controlled trials (RCTs) (n = 85) and 38 observational studies (case reports and case series) (n = 225) were included. Data extraction In RCTs, the differences in outcomes between sham and active stimulation for OCD and depression were evaluated and the proportion of responders was determined. In all included studies, at last follow-up, the improvement from baseline in OCD (Yale-Brown Obsessive Compulsive Scale [Y-BOCS score]) and a scale of weighted depression scores (WDS) were determined. Predictors of response (age, illness duration and severity, frequency parameters, and response in depression) were evaluated. The proportions of adverse events and dropouts were calculated. Results In RCTs, mean differences between sham and active stimulation in Y-BOCS and Hamilton Depression Rating Scale (HDRS) scores were -7.8 (95% CI = -11.2 to -4.3, I² = 40%, P = .0001) and -7.3 (95% CI = -11.5 to -3.0, I² = 0%, P = .0009), respectively. No differences between limbic and non-limbic targets were identified (χ² = 0.21, I² = 0%, P = .0006). At last follow-up, improvements in Y-BOCS and WDS were -15.0 (95% CI = -18.3 to -11.7, I² = 90%, P less then .001) and -13.7 (95% CI = -20.1 to -7.3, I² = 76%, P less then .001), respectively. No consistent predictors of response were found. There were 0.68 adverse events (95% CI = 0.59 to 0.78, I² = 88%), 0.32 serious adverse events (95% CI = 0.12 to 0.62, I² = 96%), and 0.13 dropouts (95% CI = 0.07 to 0.16, I² = 16%) per treated patient. Conclusions DBS can significantly decrease Y-BOCS score and depressive symptoms in refractory OCD.